Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Mirum Pharmaceuticals stock

MIRM
US6047491013
A2PM29

Price

0
Today +/-
-0
Today %
-0 %

Mirum Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Mirum Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Mirum Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Mirum Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Mirum Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Mirum Pharmaceuticals Stock Price History

DateMirum Pharmaceuticals Price
1/15/20250 undefined
1/14/202543.32 undefined
1/13/202544.00 undefined
1/10/202541.32 undefined
1/8/202542.00 undefined
1/7/202542.06 undefined
1/6/202543.09 undefined
1/3/202542.80 undefined
1/2/202542.04 undefined
12/31/202441.35 undefined
12/30/202441.18 undefined
12/27/202441.56 undefined
12/26/202442.03 undefined
12/24/202442.17 undefined
12/23/202441.73 undefined
12/20/202441.51 undefined
12/19/202441.13 undefined
12/18/202440.60 undefined

Mirum Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Mirum Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Mirum Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Mirum Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Mirum Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Mirum Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Mirum Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Mirum Pharmaceuticals’s growth potential.

Mirum Pharmaceuticals Revenue, EBIT and net profit per share

DateMirum Pharmaceuticals RevenueMirum Pharmaceuticals EBITMirum Pharmaceuticals Net Income
2030e1.08 B undefined752.19 M undefined679.56 M undefined
2029e1.16 B undefined578.43 M undefined436.48 M undefined
2028e938.36 M undefined385.56 M undefined303.06 M undefined
2027e733.35 M undefined200.65 M undefined182.87 M undefined
2026e536.12 M undefined69.16 M undefined43.1 M undefined
2025e428.34 M undefined-35.69 M undefined-37.12 M undefined
2024e339.47 M undefined-78.07 M undefined-79.91 M undefined
2023186.37 M undefined-109.15 M undefined-163.42 M undefined
202277.06 M undefined-131.22 M undefined-135.67 M undefined
202119.14 M undefined-173.41 M undefined-83.99 M undefined
20200 undefined-104.3 M undefined-103.27 M undefined
20190 undefined-54.74 M undefined-52.55 M undefined
20180 undefined-2.92 M undefined-17.35 M undefined

Mirum Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e2027e2028e2029e2030e
0000.020.080.190.340.430.540.730.941.161.08
----305.26141.5682.2626.2525.2336.7527.9724.09-6.87
---89.4783.1274.7341.0032.4825.9318.9614.8211.9412.82
00017641390000000
-17-52-103-83-135-163-79-3743182303436679
-205.8898.08-19.4262.6520.74-51.53-53.16-216.22323.2666.4843.8955.73
23.0223.0225.2530.3233.8440.890000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Mirum Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Mirum Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201820192020202120222023
           
52116.7231.8156.5151.7286.33
0003.32467.97
000000
0001.55.622.31
02.74.55.38.910.94
52119.4236.3166.6190.2387.54
03.73.22.62.31.99
023.30500
000000
00018.759252.93
000000
00.31.3101.8101.44.17
027.34.5128.1162.7259.08
52146.7240.8294.7352.9646.62
           
66.900000.01
0200.1345.2377.4535.1803.26
-17.3-69.9-173.2-257.2-392.8-556.24
00.10.10-0.21.64
000000
49.6130.3172.1120.2142.1248.67
0.33.43.29.28.77.42
2.29.71431.454.979.65
001.321.10
000000
000000
2.513.118.542.664.787.06
00000306.42
000000
03.350.3131.8146.14.47
03.350.3131.8146.1310.89
2.516.468.8174.4210.8397.95
52.1146.7240.9294.6352.9646.62
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Mirum Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Mirum Pharmaceuticals's financial health and stability.

Assets

Mirum Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Mirum Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Mirum Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Mirum Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201820192020202120222023
-17-52-103-83-135-163
0000310
0000-60
27016-21-22
141225-4366139
000006
000000
0-39-89-132-120-70
-700-190-20
-7-12737487-107
0-12738677-87
000000
00000305
591271319114227
5912718173109336
004964-5-195
000000
51-39130-10-3158
-7.87-39.64-89.31-151.78-120.42-91.05
000000

Mirum Pharmaceuticals stock margins

The Mirum Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mirum Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mirum Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Mirum Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Mirum Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Mirum Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Mirum Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Mirum Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Mirum Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Mirum Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Mirum Pharmaceuticals Margin History

Mirum Pharmaceuticals Gross marginMirum Pharmaceuticals Profit marginMirum Pharmaceuticals EBIT marginMirum Pharmaceuticals Profit margin
2030e74.76 %69.39 %62.69 %
2029e74.76 %49.69 %37.5 %
2028e74.76 %41.09 %32.3 %
2027e74.76 %27.36 %24.94 %
2026e74.76 %12.9 %8.04 %
2025e74.76 %-8.33 %-8.67 %
2024e74.76 %-23 %-23.54 %
202374.76 %-58.57 %-87.68 %
202283.95 %-170.28 %-176.06 %
202190.07 %-906.01 %-438.82 %
202074.76 %0 %0 %
201974.76 %0 %0 %
201874.76 %0 %0 %

Mirum Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Mirum Pharmaceuticals earnings per share therefore indicates how much revenue Mirum Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Mirum Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Mirum Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Mirum Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mirum Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Mirum Pharmaceuticals Revenue, EBIT and net profit per share

DateMirum Pharmaceuticals Sales per ShareMirum Pharmaceuticals EBIT per shareMirum Pharmaceuticals Earnings per Share
2030e22.58 undefined0 undefined14.16 undefined
2029e24.25 undefined0 undefined9.09 undefined
2028e19.55 undefined0 undefined6.31 undefined
2027e15.28 undefined0 undefined3.81 undefined
2026e11.17 undefined0 undefined0.9 undefined
2025e8.92 undefined0 undefined-0.77 undefined
2024e7.07 undefined0 undefined-1.66 undefined
20234.56 undefined-2.67 undefined-4 undefined
20222.28 undefined-3.88 undefined-4.01 undefined
20210.63 undefined-5.72 undefined-2.77 undefined
20200 undefined-4.13 undefined-4.09 undefined
20190 undefined-2.38 undefined-2.28 undefined
20180 undefined-0.13 undefined-0.75 undefined

Mirum Pharmaceuticals business model

Mirum Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and marketing of therapeutics for rare intestinal diseases. The company was founded in 2018 in California, USA and has experienced rapid growth since then. The company was founded after an unusual event in 2015 when Shire Pharmaceuticals plc, a large British pharmaceutical company, acquired the biotech company Lumena Pharmaceuticals Inc. The management of Lumena discovered a compound that they believed could relieve cholestasis, a condition where bile cannot flow adequately and therefore remains in the liver. They realized that this compound, if modified and used in a new formulation, could also be used to treat other rare intestinal diseases. The management of Lumena decided to pursue this idea and thus founded Mirum Pharmaceuticals Inc. The company's business model is to develop novel medications for the treatment of severe and rare intestinal diseases through a combination of in-house research and external collaborations. Mirum Pharmaceuticals Inc aims to fill a niche focusing on smaller patient populations that are often overlooked by larger pharmaceutical companies due to their rarity. The company also aims to work closely with patients and their families to ensure that their needs and concerns are incorporated into their product development processes. Currently, Mirum Pharmaceuticals Inc's research and development efforts focus on two main areas: cholestasis and intestinal enteropathies. Cholestasis is a condition where the liver is unable to secrete bile into the intestine, resulting in the accumulation of bile in the body and damage to liver cells and other organs. Mirum Pharmaceuticals Inc is currently developing Maralixibat, a medication targeting the treatment of intrahepatic cholestasis in children. Intestinal enteropathies are rare intestinal diseases characterized by a disruption of the intestinal tract. Mirum Pharmaceuticals Inc is dedicated to researching and developing a medication for the treatment of PFIC, a rare condition where bile fluid is no longer adequately excreted. In this regard, the company has entered into an agreement with Dova Pharmaceuticals Inc., which was acquired by Merck&Co. in mid-2019. Under this agreement, Mirum Pharmaceuticals Inc acquired the rights to a medication for the treatment of PFIC developed by Dova. Mirum Pharmaceuticals solutions aim to treat patients on a relevant basis and provide support for families and caregivers of patients. In summary, Mirum Pharmaceuticals Inc is a biopharmaceutical company that emerged from a spin-out of Lumena Pharmaceuticals Inc from Shire. It has focused on the development of therapeutics for rare intestinal diseases and works closely with patients and their families to ensure their concerns are considered in product development processes. The product research of Mirum Pharmaceuticals Inc currently focuses on Maralixibat, a medication for the treatment of intrahepatic cholestasis, as well as Mirum Pharmaceuticals Inc, a medication for the treatment of PFIC. Mirum Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Mirum Pharmaceuticals SWOT Analysis

Strengths

Mirum Pharmaceuticals Inc has several strengths that contribute to its success in the pharmaceutical industry. These strengths include:

  • Strong financial position and funding support, allowing for investment in research and development.
  • Advanced technology and expertise in developing innovative treatments for rare liver diseases.
  • Strong network of strategic partnerships with key stakeholders including healthcare providers, regulatory bodies, and patient advocacy groups.
  • Experienced and dedicated team of professionals with deep industry knowledge and expertise.

Weaknesses

Despite its strengths, Mirum Pharmaceuticals Inc also faces certain weaknesses, which need to be addressed to maintain its competitive edge:

  • Relatively small size compared to some major pharmaceutical companies, limiting resources and scale of operations.
  • Dependence on a limited portfolio of products, reducing diversification and exposing the company to market fluctuations.
  • Challenges in obtaining regulatory approvals and ensuring compliance in multiple jurisdictions.
  • High research and development costs, putting pressure on profitability and cash flow.

Opportunities

Mirum Pharmaceuticals Inc can leverage various opportunities to drive growth and expansion in the market:

  • Increasing demand for effective treatments for rare liver diseases, particularly with the rising prevalence of such conditions.
  • Potential for partnerships and collaborations with academic institutions and research organizations to accelerate innovation and drug development.
  • Expansion into new geographical markets to reach a wider patient population and increase revenue streams.
  • Exploring acquisition or licensing opportunities to enhance product pipeline and diversify the portfolio.

Threats

Mirum Pharmaceuticals Inc faces several threats that could impede its growth and performance:

  • Intense competition from larger pharmaceutical companies with greater resources and established market presence.
  • Stringent regulatory requirements and potential delays in obtaining approvals for new drugs.
  • Pricing pressures and reimbursement challenges in healthcare systems globally.
  • Emergence of alternative therapies or breakthroughs that could render Mirum's treatments less effective or obsolete.

Mirum Pharmaceuticals Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Mirum Pharmaceuticals Revenue by Segment

Segmente2021
License16 M USD
Product3.14 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Mirum Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Mirum Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Mirum Pharmaceuticals shares outstanding

The number of shares was Mirum Pharmaceuticals in 2024 — This indicates how many shares 40.885 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Mirum Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Mirum Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Mirum Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mirum Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Mirum Pharmaceuticals.

Mirum Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.46 -0.3  (34.54 %)2024 Q3
6/30/2024-0.48 -0.52  (-7.95 %)2024 Q2
3/31/2024-0.49 -0.54  (-10.52 %)2024 Q1
12/31/2023-0.25 -0.66  (-166.24 %)2023 Q4
9/30/2023-0.64 -0.57  (11.08 %)2023 Q3
6/30/2023-0.81 -1.94  (-139.12 %)2023 Q2
3/31/2023-0.96 -0.8  (16.41 %)2023 Q1
12/31/2022-1.04 -0.99  (4.8 %)2022 Q4
9/30/2022-1.09 -1.02  (6.52 %)2022 Q3
6/30/2022-1.18 -0.84  (28.6 %)2022 Q2
1
2
3

Eulerpool ESG Scorecard© for the Mirum Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

37/ 100

🌱 Environment

37

👫 Social

57

🏛️ Governance

17

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Mirum Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
13.53207 % Frazier Life Sciences Management, L.P.6,495,39206/30/2024
10.39322 % Janus Henderson Investors4,988,7472,221,5376/30/2024
9.10422 % BVF Partners L.P.4,370,02406/30/2024
7.53087 % Eventide Asset Management, LLC3,614,820314,4206/30/2024
6.11390 % BlackRock Institutional Trust Company, N.A.2,934,672680,1326/30/2024
5.08164 % The Vanguard Group, Inc.2,439,185233,2656/30/2024
3.69175 % Rock Springs Capital Management LP1,772,038-84,5266/30/2024
3.30338 % Citadel Advisors LLC1,585,624193,1186/30/2024
3.12500 % Novo Holdings A/S1,500,00009/30/2024
3.11712 % State Street Global Advisors (US)1,496,217-1,326,2556/30/2024
1
2
3
4
5
...
10

Mirum Pharmaceuticals Executives and Management Board

Mr. Christopher Peetz

(44)
Mirum Pharmaceuticals Chief Executive Officer, Co-Founder, Director (since 2018)
Compensation 4.4 M

Mr. Peter Radovich

(45)
Mirum Pharmaceuticals President, Chief Operating Officer
Compensation 1.56 M

Ms. Lara Longpre

(53)
Mirum Pharmaceuticals Chief Development Officer
Compensation 1.51 M

Dr. Pamela Vig

(52)
Mirum Pharmaceuticals Head of Research and Development
Compensation 1.51 M

Ms. Saira Ramasastry

(47)
Mirum Pharmaceuticals Independent Director
Compensation 597,632
1
2
3

Mirum Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Takeda Pharmaceutical Stock
Takeda Pharmaceutical
SupplierCustomer0,810,260,560,910,360,29
Sanofi Stock
Sanofi
SupplierCustomer0,660,580,750,860,780,36
Pfizer Stock
Pfizer
SupplierCustomer0,130,150,60-0,380,390,02
CANbridge Pharmaceuticals Stock
CANbridge Pharmaceuticals
SupplierCustomer-0,19-0,25-0,48
1

Most common questions regarding Mirum Pharmaceuticals

What values and corporate philosophy does Mirum Pharmaceuticals represent?

Mirum Pharmaceuticals Inc represents values of integrity, innovation, and patient-centricity. With a strong corporate philosophy, the company is committed to developing transformative therapies for patients with rare liver diseases. By focusing on unmet medical needs, Mirum aims to improve the lives of patients by providing innovative treatment options and advocating for the rare disease community. Mirum Pharmaceuticals Inc prioritizes scientific excellence, collaborative partnerships, and a deep sense of responsibility towards patients and their families. Through their dedication and novel approach, Mirum Pharmaceuticals Inc continues to make significant advancements in the field of rare liver diseases.

In which countries and regions is Mirum Pharmaceuticals primarily present?

Mirum Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Mirum Pharmaceuticals achieved?

Mirum Pharmaceuticals Inc has achieved several significant milestones. The company successfully completed its initial public offering in July 2019, raising approximately $75 million in gross proceeds. In December 2020, Mirum received accelerated approval from the U.S. Food and Drug Administration (FDA) for its first product, Maralixibat, to treat a rare liver disease called progressive familial intrahepatic cholestasis type 2 (PFIC2). This milestone marked a major breakthrough in providing a treatment option for patients suffering from this debilitating condition. Mirum continues to drive innovation in the field of rare liver diseases, aiming to improve the lives of patients worldwide.

What is the history and background of the company Mirum Pharmaceuticals?

Mirum Pharmaceuticals Inc, founded in 2018, is a biopharmaceutical company dedicated to developing and delivering innovative therapies for patients with rare cholestatic liver diseases and other serious liver disorders. Headquartered in Foster City, California, Mirum focuses on conducting clinical trials, obtaining regulatory approvals, and commercializing therapies to address critical unmet needs. The company's pipeline includes maralixibat, an investigational drug designed to treat rare pediatric cholestatic liver diseases such as progressive familial intrahepatic cholestasis and Alagille syndrome. Mirum Pharmaceuticals Inc is committed to improving the lives of patients affected by these uncommon liver disorders through its research and development efforts.

Who are the main competitors of Mirum Pharmaceuticals in the market?

The main competitors of Mirum Pharmaceuticals Inc in the market include companies such as Alnylam Pharmaceuticals, ProQR Therapeutics, and Madrigal Pharmaceuticals.

In which industries is Mirum Pharmaceuticals primarily active?

Mirum Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Mirum Pharmaceuticals?

Mirum Pharmaceuticals Inc's business model focuses on developing and commercializing innovative therapies for patients with liver diseases. The company aims to address unmet medical needs in areas such as cholestatic liver diseases, including Alagille syndrome and progressive familial intrahepatic cholestasis. Mirum Pharmaceuticals Inc leverages its expertise in liver biology to identify and develop potential drug candidates that have the potential to improve patients' lives. By targeting specific liver diseases, Mirum Pharmaceuticals Inc aims to provide effective and targeted treatments for patients in need.

What is the P/E ratio of Mirum Pharmaceuticals 2025?

The P/E ratio cannot be calculated for Mirum Pharmaceuticals at the moment.

What is the P/S ratio of Mirum Pharmaceuticals 2025?

The P/S cannot be calculated for Mirum Pharmaceuticals currently.

What is the Quality Investing of Mirum Pharmaceuticals?

The Quality Investing for Mirum Pharmaceuticals is 2/10.

What is the revenue of Mirum Pharmaceuticals 2025?

The expected Mirum Pharmaceuticals revenue is 428.34 M USD.

How high is the profit of Mirum Pharmaceuticals 2025?

The expected Mirum Pharmaceuticals profit is -37.12 M USD.

What is the business model of Mirum Pharmaceuticals

Mirum Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing drugs for the treatment of rare liver diseases. The company was founded in 2018 and is headquartered in Foster City, California.

What is the Mirum Pharmaceuticals dividend?

Mirum Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Mirum Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Mirum Pharmaceuticals or the company does not pay out a dividend.

What is the Mirum Pharmaceuticals ISIN?

The ISIN of Mirum Pharmaceuticals is US6047491013.

What is the Mirum Pharmaceuticals WKN?

The WKN of Mirum Pharmaceuticals is A2PM29.

What is the Mirum Pharmaceuticals ticker?

The ticker of Mirum Pharmaceuticals is MIRM.

How much dividend does Mirum Pharmaceuticals pay?

Over the past 12 months, Mirum Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mirum Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Mirum Pharmaceuticals?

The current dividend yield of Mirum Pharmaceuticals is .

When does Mirum Pharmaceuticals pay dividends?

Mirum Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mirum Pharmaceuticals?

Mirum Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Mirum Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mirum Pharmaceuticals located?

Mirum Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mirum Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mirum Pharmaceuticals from 1/16/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/16/2025.

When did Mirum Pharmaceuticals pay the last dividend?

The last dividend was paid out on 1/16/2025.

What was the dividend of Mirum Pharmaceuticals in the year 2024?

In the year 2024, Mirum Pharmaceuticals distributed 0 USD as dividends.

In which currency does Mirum Pharmaceuticals pay out the dividend?

The dividends of Mirum Pharmaceuticals are distributed in USD.

All fundamentals about Mirum Pharmaceuticals

Our stock analysis for Mirum Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mirum Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.